About 31 results found for searched term "Z-D-tyrosine" (0.111 seconds)
| Cat.No. | Name | Target |
|---|---|---|
| M52297 | Z-D-tyrosine | Amino Acid Derivatives |
| Z-D-tyrosine is a tyrosine derivative. | ||
| M1749 | Gefitinib | EGFR/HER2 |
| ZD-1839, Iressa | ||
| Gefitinib (ZD1839) is an EGFR tyrosine kinase and Akt phosphorylation inhibitor. Gefitinib significantly down-regulates CD47 expression and increases DC phagocytosis in non-small cell lung cancer cells such as PC9, H1437 and H1573. Gefitinib combined with CD47 antibody can enhance the phagocytosis of macrophages. | ||
| M3238 | 4-Quinazolinamine | EGFR/HER2 |
| 4-Aminoquinazoline, NSC 288012 | ||
| 4-Quinazolinamine (4-Aminoquinazoline) is a potent and highly selective EGFR tyrosine kinase inhibitor. | ||
| M4596 | Silydianin | Phosphatase |
| Silydianin, the active ingredient of silythistle, has anti-collagenase and anti-elastic enzyme activities. Silydianin is a natural protein tyrosine phosphatase 1B (PTP1B) inhibitor with an IC50 value of 17.38 μM. Silydianin inhibited the production and release of oxidation products in vitro. | ||
| M5313 | AZD2932 | VEGFR/PDGFR |
| AZD2932 is a potent and mutil-targeted protein tyrosine kinase inhibitor with IC50 of 8 nM, 4 nM, 7 nM, and 9 nM for VEGFR-2, PDGFRβ, Flt-3, and c-Kit, respectively. | ||
| M5316 | BLZ945 (Sotuletinib) | CSF-1R (c-Fms) |
| Sotuletinib | ||
| Sotuletinib (BLZ945) is an orally active, potent and selective CSF-1R inhibitor with IC50 of 1 nM, >1000-fold selective against its closest receptor tyrosine kinase homologs. | ||
| M9465 | MAZ51 | VEGFR/PDGFR |
| MAZ-51 | ||
| MAZ51 is originally synthesized inhibitor of VEGFR-3 (Flt-4) tyrosine kinase, inhibits VEGF-C-induced activation of VEGFR-3 without blocking VEGF-C-mediated stimulation of VEGFR2. | ||
| M9548 | CZC-8004 | Src-bcr-Abl |
| CZC-00008004 | ||
| CZC-8004 is a pan-kinase inhibitor and binds a range of tyrosine kinases, including ABL kinase. | ||
| M9938 | Lazertinib | EGFR/HER2 |
| YH-25448; GNS-1480 | ||
| Lazertinib, also known as YH-25448 and GNS-1480, is an oral active, highly potent, mutant-selective and irreversible EGFR Tyrosine-kinase inhibitors (TKIs) targets both the T790M mutation and activating EGFR mutations while sparing wild type-EGFR. | ||
| M10025 | Zanubrutinib | BTK |
| BGB-3111 | ||
| Zanubrutinib (BGB-3111) is a potent and highly selective small molecule inhibitor of Bruton's tyrosine kinase (BTK). | ||
| M10605 | Rilzabrutinib | BTK |
| PRN1008 | ||
| Rilzabrutinib, also known as PRN1008, is a reversible covalent, selective and oral active inhibitor of Bruton’s Tyrosine Kinase (BTK) with IC50 of 1.3 nM. | ||
| M14879 | (±)-Zanubrutinib | BTK |
| (±)-BGB-3111 | ||
| (±)-Zanubrutinib ((±)-BGB-3111) is a potent, selective and orally available Bruton's tyrosine kinase (Btk) inhibitor. | ||
| M20883 | 3-Nitro-L-tyrosine | Adrenergic Receptor |
| 3-NT, N-Tyr, MNT | ||
| 3-Nitro-L-tyrosine (3-NT, N-Tyr, MNT), synthesized from L-tyrosine by peroxynitrite, is a product of nitric oxide and superoxide. 3-Nitro-L-tyrosine inhibits the hemodynamic responses to angiotensin II, possibly through the inhibition of alpha 1-adrenoceptor-mediated events. | ||
| M24854 | Ianalumab | Others |
| VAY-736 | ||
| Ianalumab (VAY-736) is a humanized, decarboxylated antibody against BAFF-R. Ianalumab can block the interaction between BAFF and BAFF-R and antagonize the apoptosis protection mediated by BAFF. Ianalumab exerts antibody-dependent cytotoxic (ADCC), depending on effector cell activation mediated by immune receptor tyrosine activation motif (ITAM). | ||
| M25171 | Ozuriftamab | Others |
| Ozuriftamab is a naked human IgG1 kappa antibody of receptor tyrosine kinase-like orphan receptor 2 ROR2, can be used to synthesis ADC. | ||
| M28550 | SDZ281-977 | EGFR/HER2 |
| SDZ-LAP 977 | ||
| SDZ 281-977 is a derivative of the EGF receptor tyrosine kinase inhibitor Lavendustin A. | ||
| M28692 | Bezuclastinib | c-Kit |
| CGT9486; PLX 9486 | ||
| Bezuclastinib (CGT9486; PLX 9486) is a potent inhibitor of c-kit and c-kit D816V (0.0001 < IC50 < 1 μM). Bezuclastinib is a tyrosine kinase inhibitor. | ||
| M29911 | BRD9876 | Kinesin |
| BRD9876 is the “rigor” inhibitor that locks kinesin-5 (Eg5) in a state with enhanced microtubules (MTs) binding, leading to bundling and stabilization of MTs. BRD9876 interacts with the tyrosine 104 residue that is part of the α4-α6 allosteric binding pocket. BRD9876 specifically targets microtubule-bound Eg5 and selectively inhibits myeloma over CD34 cells. BRD9876 has the potential for multiple myeloma (MM) research. | ||
| M30609 | FG 7142 | GABA Receptor |
| ZK 39106; LSU-65 | ||
| FG 7142 (ZK 39106; LSU-65), a non-selectively benzodiazepine inverse agonist, has high affinity for the α1 subunit-containing GABAA receptor (Ki=91 nM). FG 7142 (ZK 39106; LSU-65) also modulates GABA-induced chloride flux at GABAA receptors expressing the α1 subunit (EC50= 137 nM). FG 7142 (ZK 39106; LSU-65) can increase tyrosine hydroxylation and cause upregulation of β-adrenoceptors in mouse cerebral cortex. | ||
| M30779 | ZAP-180013 | Tyrosinase |
| ZAP-180013 is a zeta-chain-associated protein kinase 70 (ZAP-70) inhibitor with an IC50 of 1.8 μM. ZAP-180013 inhibits the interaction of ZAP-70 SH2 domain with immunoreceptor tyrosine-based activation motif (ITAMs). | ||
| M39071 | Gefitinib impurity 1 | Metabolite/Endogenous Metabolite |
| Gefitinib impurity 1 is the impurity of Gefitinib. Gefitinib (ZD1839) is a potent, selective and orally active EGFR tyrosine kinase inhibitor with an IC50 of 33 nM. Gefitinib selectively inhibits EGF-stimulated tumor cell growth (IC50 of 54 nM). | ||
| M40621 | DZD1516 | EGFR/HER2 |
| DZD1516 is an orally active, potent, reversible, and selective HER2 small molecule tyrosine kinase inhibitors (TKIs) with an IC50 value of 0.56 nM, which completely penetrates the blood-brain barrier. It can be used in studies related to HER2-positive breast cancer. | ||
| M40671 | Nyuzenamide A | Antifungal |
| Nyuzenamide A is a cyclic peptide with a heterodityrosine bond found in aquatic bacteria of the genus Streptomyces with cytotoxic and antifungal activity. | ||
| M40672 | Nyuzenamide B | Antifungal |
| Nyuzenamide B is a cyclic peptide with a heterodityrosine bond found in aquatic bacteria of the genus Streptomyces with cytotoxic and antifungal activity. | ||
| M40673 | Nyuzenamide C | Others |
| Nyuzenamide C, a cyclic peptide with a heterodityrosine bond found in aquatic bacteria of the genus Streptomyces, bearing a cinnamic acid structural unit, showed anti-angiogenic activity in cell culture assays. | ||
| M43536 | TIE-2/VEGFR-2 kinase-IN-3 | VEGFR/PDGFR |
| TIE-2/VEGFR-2 kinase-IN-3, benzimidazole, is a potent TIE-2 and VEGFR-2 tyrosine kinase receptors inhibitors with IC50 values of 6.9 nM and 3.5 nM, respectively. | ||
| M43537 | TIE-2/VEGFR-2 kinase-IN-4 | VEGFR/PDGFR |
| TIE-2/VEGFR-2 kinase-IN-4, benzimidazole, is a potent TIE-2 and VEGFR-2 tyrosine kinase receptors inhibitors with IC50 values of 5.2 nM and 5.1 nM, respectively. | ||
| M45386 | Rezivertinib | EGFR/HER2 |
| BPI-7711 | ||
| Rezivertinib is an orally effective, highly selective and irreversible third-generation EGFR tyrosine kinase inhibitor (TKI) with high potency against common activating EGFR and resistant T790M mutations.Rezivertinib exhibits excellent CNS penetration and antitumor activity. | ||
| M50176 | Saracatinib difumarate | Src-bcr-Abl |
| AZD0530 difumarate | ||
| Saracatinib (AZD0530) difumarate is a potent Src inhibitor with IC50 values of 2.7-11 nM for c-Src, Lck, c-YES, Lyn, Fyn, Fgr and Blk, and it is selective for other tyrosine kinases. | ||
| M51307 | Cyclo(Arg-Gly-Asp-D-Tyr-ε-azido-Nle) | Others |
| Cyclo(Arg-Gly-Asp-D-Tyr-ε-azido-Nle) (Azido-c(RGDyK)) is a polypeptide composed of arginine, glycine, aspartic acid, and tyrosine that can be used for Synthesis of [18F]FPyKYNE-c(RGDyK). | ||
| M51801 | Z-Tyr(tBu)-OH.DCHA | Amino Acid Derivatives |
| Z-Tyr(tBu)-OH.DCHA is a tyrosine derivative. | ||
Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2024 AbMole BioScience. All Rights Reserved.
